Dendritic cells (DCs), a type of professional antigen-presenting cells, are responsible for initiation and maintenance of immune responses. Here we report that a substantial proportion of DCs in tumor-bearing mice and people with cancer have high amounts of triglycerides as compared with DCs from tumor-free mice and healthy individuals. In our studies, lipid accumulation in DCs was caused by increased uptake of extracellular lipids due to upregulation of scavenger receptor A. DCs with high lipid content were not able to effectively stimulate allogeneic T cells or present tumor-associated antigens. DCs with high and normal lipid levels did not differ in expression of major histocompatibility complex and co-stimulatory molecules. However, lipid-laden DCs had a reduced capacity to process antigens. Pharmacological normalization of lipid abundance in DCs with an inhibitor of acetyl-CoA carboxylase restored the functional activity of DCs and substantially enhanced the effects of cancer vaccines. These findings suggest that immune responses in cancer can be improved by manipulating the lipid levels in DCs.
DCs are cells specializing in acquisition, processing and presentation of antigens to T cells. Defective function of DCs in cancer contri butes greatly to tumor evasion of immune control 1, 2 . It is established that the defects in DC function in cancer are mediated by various tumorderived factors 1 . However, the mechanism by which these fac tors affect DCs remains unclear. During investigation of the effects of tumorderived factors on DC differentiation, we unexpectedly observed accumulation of lipids in DCs generated in the presence of tumor cell-conditioned medium (Supplementary Fig. 1) . These findings prompted us to investigate the potential role of lipid accu mulation in DC function in cancer. Lipids represent a diverse group of low-molecularweight molecules. Most lipid molecules contain fatty acid moieties 3 . Lipids are a key energy resource and a major structural component of the membrane matrix, and they are involved in signaling regulating function of various cell types 4 .
The factors affecting storage, uptake and metabolism of the various fatty acids in DCs may have an impact on the function of the immune system 5 . A number of studies have shown the nega tive effect of dietary lipids on DC function [6] [7] [8] [9] [10] [11] [12] [13] [14] (Supplementary  Discussion) . These data indicate that lipids could be a crucial factor regulating DC function. However, their exact role in DC activity remains unclear. There is very little information regarding the biological or clinical role of lipid accumulation in DCs in cancer.
Here we report our finding that accumulation of lipids in DCs not only is a consistent phenomenon found in tumorbearing hosts but also has a profound effect on DC function.
RESULTS

Lipid accumulation in DCs
To evaluate the amount of lipids in DCs, we used the lipophilic fluo rescent dye BODIPY 493/503. CD11c + DCs isolated from spleens of mice bearing EL4 lymphoma showed more fluorescence than their control counterparts ( Fig. 1a) . By flow cytometry we detected two populations of CD11c + DCs in tumorbearing mice. One popula tion, termed DCs with normal lipid content (DCsNL), represented 30-50% of cells and had a similar level of fluorescence to control DCs (Fig. 1b) . The other population (50-70% of cells), referred to as DCs with high lipid content (DCsHL), had fluorescence higher than that in control DCs (Fig. 1b) . The level of lipids in spleen DCs was elevated in all four tested tumor models (EL4 lymphoma, DA3 mammary adeno carcinoma, CT26 and MC38 colon adenocarcinomas) in C56BL/6 and BALB/c mice as compared with DCs from control mice (Fig. 1c) , and it increased with tumor progression (Fig. 1d) . We observed high lipid levels in CD11c + CD8 + DCs and CD11c + CD11b + B220 − conven tional DCs (cDCs) but not in CD11c + CD11b − B220 + plasmacytoid DCs (pDCs) (Fig. 1e) . We measured the lipid content in tumors as well as several DCcontaining compartments (blood, lymph nodes and bone marrow). In tumorbearing mice, DCs isolated from tumors had higher levels of lipids than DCs from blood and lymph nodes ( Fig. 1f) . DCs from the lymph nodes, bone marrow and blood from tumorbearing mice had higher levels of lipids than DCs from control mice (Fig. 1g) . In DCs from tumordraining lymph nodes, the lipid content was elevated to the same extent as in DCs from distant lymph nodes ( Fig. 1h) .
To evaluate the nature of these lipids, we isolated CD11c + DCs from spleens of naive and tumorbearing mice. We extracted total lipids and analyzed them by highperformance thinlayer chromatography (HPTLC), and electrospray ionization mass spectroscopy (ESIMS). DCs from tumorbearing mice showed markedly higher levels of triglycerides (triacylglycerol) than cells from naive mice ( Fig. 1i) . In contrast, we found no differences in serum triacylglycerol level between naive and tumorbearing mice ( Fig. 1i) . Most of the molecu lar species of triacylglycerol were elevated in DCs from tumorbearing mice as compared with their control counterparts ( Supplementary  Fig. 2a ), and we found no differences in the profiles of major molecu lar species of triacylglycerol between serum samples from naive and tumorbearing mice (data not shown). In contrast to triacylglycerol levels, we observed no changes in the levels of cholesteryl esters and phospholipids ( Supplementary Fig. 2b,c) .
Lipid levels were also evaluated in DCs from 12 individuals with headandneck cancer (HNC) by BODIPY staining. Peripheral blood, draining lymph nodes and tumor tissues were collected during sur gery. DCs were identified as Lin − CD4 + cells 15 (Fig. 2a) . DCs from peripheral blood of individuals with cancer showed significantly higher levels of lipids than peripheral blood DCs from the healthy individuals (Fig. 2b) . The lipid level in DCs from lymph nodes and tumors was considerably higher than that in DCs from peripheral blood ( Fig. 2b) . We obtained similar findings in cohorts of individuals with nonsmall lung cancer and renal cell cancer ( Fig. 2c) . In separate experiments, we found that lymph node DCs from individuals with HNC contained a significantly higher level of lipids than lymph node DCs from individuals with benign tumors (Fig. 2d) . Thus, these data strongly corroborate those obtained from mouse tumor models and indicate that in mouse tumor models and subjects with different types of cancer there is an upregulation of the DC lipid content.
Mechanism of lipid accumulation in DCs
To study the mechanisms of lipid accumulation in DCs, we generated DCs in vitro from bone marrow progenitors (BMPs) by using granulocytemacrophage colony-stimulating factor and interleukin4. We incubated in vitro-generated DCs with tumor explant supernatants (TESs) for 24-72 h. This resulted in a more than threefold increase in the lipid level ( Fig. 3a) . Analysis of lipid content by ESIMS revealed that DCs generated in the presence of TES had an almost sixfold higher level of triacylglycerol than DCs generated in control culture medium ( Fig. 3b) . There was an increase in the level of all molecular species of triacylglycerol, but we observed no changes in the level of phospholipids and cholesteryl esters in these DCs ( Supplementary  Fig. 3 ). The total level of triacylglycerol in CT26 TES was more than four times higher than in control medium ( Fig. 3b) . Despite the variability in triacylglycerol level in TES obtained from various tumor cell lines, they all caused comparable upregulation of lipids in DCs (Supplementary Fig. 4) .
To directly evaluate fatty acid uptake, we incubated DCs for 24 h in the presence of TES, washed cells and then treated them with fluorescently labeled palmitic fatty acid for 30 min at 37 °C. DCs preincubated with TES had markedly higher uptake of fatty acid than DCs incubated in control medium (Fig. 3c) of DCs from spleens of tumorbearing mice in serumfree medium eliminated elevated level of lipids in these cells while not affecting the level of lipids in control DCs (data not shown). These data suggest that increased uptake of lipids may be the major mechanism of lipid accumulation by DCs. We next investigated why DCs from tumorbearing hosts have higher lipid uptake than those from controls. Scavenger receptors have a major role in intracellular transport of lipids. Currently, little is known about changes in their expression on DCs from tumorbearing hosts. Therefore, we evaluated the level of four major scavenger recep tors (macrophage scavenger receptor (Msr1, or CD204), Cd36 (Srb), Cd68 and macrophage receptor with collagenous structure). EL4 TES caused significant upregulation of the expression of Msr1 in DCs (Fig. 3d) . This was associated with increased expression of this recep tor on the surface of DCs (Fig. 3e) . We observed a similar effect with TES from CT26 and B16F10 tumors (data not shown). Expression of mRNA for only one scavenger receptor-Msr1 was significantly ele vated in DCs from tumorbearing mice ( Fig. 3f) . cDCs from tumor bearing mice had threefold higher protein expression of Msr1 than their control counterparts ( Fig. 3g) . In contrast, we did not observe any upregulation of Msr1 in pDCs ( Fig. 3g) . We found no differ ences in the expression of Msr1 protein between DCs from naive mice and DCsNL from tumorbearing mice. (Fig. 3h) . However, DCsHL expressed substantially higher Msr1 protein ( Fig. 3h) . We obtained similar results in experiments in vitro (Supplementary Fig. 5a ). We detected elevated Msr1 expression in DCs from all tested sites of tumorbearing mice, and the expression of Msr1 in DCs isolated from tumors was 20 to 50fold higher than in other sites ( Supplementary  Fig. 5b) . Thus, the pattern of Msr1 expression was similar to that of the lipid increase and suggested that upregulation of this receptor might be involved in lipid accumulation in DCs.
To directly test this hypothesis, we used fucoidan, a soluble lig and that prevents binding of natural ligands to scavenger recep tors. Fucoidan did not affect DC viability but completely abrogated the effect of CT26 TES on lipid accumulation (data not shown). Preincubation of DCs with neutralizing antibodies to Msr1 com pletely abrogated the effect of TES on lipid accumulation, whereas Cd36specific antibody had little effect ( Fig. 3i) . We generated DCs from BMPs of wildtype and Msr1 −/− C57BL/6 mice (CD45.2 + ). We transferred these DCs intravenously (i.v.) into sublethally irradiated congenic (CD45.1 + ) tumorfree or EL4 tumor-bearing recipients. Two days later, we evaluated the level of lipids in CD45.2 + donor's cells isolated from recipient spleens. Donor DCs in tumorbearing recipi ents showed significantly higher levels of lipids than cells in tumor free recipients (Fig. 3j) . In contrast, DCs generated from Msr1 −/− mice failed to accumulate lipids after transfer to tumorbearing recipients ( Fig. 3j) . Analysis of triacylglycerol content by ESIMS showed that, in contrast to wildtype DCs, Msr1deficient DCs did not accumulate triacylglycerol during the culture with CT26 TES ( Supplementary  Fig. 6 ). Taken together, these data indicate that upregulation of Msr1 has a major role in accumulation of lipids in DCs in cancer.
Functional activity of lipid-laden DCs
To investigate whether lipid accumulation in DCs has functional con sequences, DCsHL and DCsNL from spleens of control and CT26 tumorbearing mice were sorted using the gates set around lipid levels in control DCs ( Fig. 4a ) and then used for stimulation of allogeneic T cells. DCs from control mice and DCsNL from tumorbearing mice had similar effects on allogeneic T cell proliferation, whereas DCsHL from tumorbearing mice had substantially lower stimulatory activity ( Fig. 4b) . We obtained similar results with in vitro-generated DCs cultured for 48 h with TES ( Fig. 4c) .
Msr1specific antibody abrogated the negative effects of TESs on DC function ( Fig. 4d) . TES inhibited the ability of DCs gener ated from wildtype BMPs to stimulate allogeneic T cells, whereas it did not affect this function of DCs generated from Msr1 −/− BMPs (Fig. 4e ).
Next, we tested the ability of DCs with various lipid contents to stimulate antigenspecific T cell responses. DCsNL and DCsHL iso lated from EL4 tumor-bearing mice equally stimulated responses of transgenic CD4 + or CD8 + T cells to ovalbumin (OVA)derived specific peptides ( Fig. 4f,g) . However, we obtained different results when we loaded DCs overnight with soluble protein (OVA). CD11c + DCs from tumorbearing mice had a reduced ability to stimulate proliferation of OVAspecific CD4 + T cells ( Fig. 4h) . DCsNL from tumorbearing mice and control DCs showed similar activity in stimulation of OVAspecific CD4 + (Fig. 4i ) and CD8 + (Fig. 4j ) T cells, whereas DCsHL induced a substantially lower response. Thus DCsHL had substantially reduced capacity to stimulate T cells when it required processing of antigen.
Presentation of antigens by lipid-laden DCs
The decreased ability of lipidladen DCs to present antigens asso ciated with soluble proteins could be caused by differences in the maturation state of the cells. To test this possibility, we compared the phenotypes of CD11c + DCs with normal and high lipid content from tumorbearing mice. We found no differences in the propor tion of DCs expressing markers of macrophages or granulocytes (F4/80 and Gr1) or in the level of expression of these markers between DCsNL and DCsHL (Supplementary Fig. 7a ). Although DCs from tumorbearing mice had markedly lower expression of major histocompatibility complex (MHC) class I and II and costimulatory molecules (CD40, CD86 and CD80) than DCs from naive mice, we found no differences between DCsNL and DCsHL (Supplementary Fig. 7b) .
The other possible possible explanation might be a decreased uptake of soluble proteins by DCsHL. To test this possibility, we incu bated DCs generated from BMPs in the presence of TES with OVA fluorescently labeled with allophycocyanin (APC). DCsNL had the same levels of OVA uptake as control DCs, whereas DCsHL showed significantly higher fluorescence levels of OVAAPC (Fig. 5a) . We obtained similar results in vivo after injection of EL4 tumor-bearing mice intraperitoneally with OVAAPC ( Fig. 5b) . Thus, DCsHL inter nalized more soluble protein than DCsNL.
To assess the ability of DCs to process antigen, we used BSADQ, a selfquenching conjugate of bovine serum albumin that shows fluo rescence upon proteolytic degradation. To normalize for increased protein uptake by DCsHL, we determined the ratio of OVAFITC to BSADQ fluorescence after loading DCs with these proteins. DCs isolated from tumorbearing mice or cultured with TES had a sub stantially lower BSADQ to OVAFITC ratio than DCs from control mice or cells cultured in control medium (Fig. 5c) . We observed this effect at all tested time points (Fig. 5d) . To verify these observations, we used the 25d1.16 antibody, which recognizes the OVAderived epitope bound to H2K b (pMHC). CD11c + DCs isolated from the spleens of EL4 tumor-bearing or control mice were loaded with OVA overnight and then stained with 25D1.16 antibody. The binding of this antibody to DCs from tumorbearing mice was lower than to DCs from control mice (Fig. 5e) . DCs generated from BMPs in the pres ence of TES were loaded with OVA and then stained with BODIPY and pMHCspecific antibody. DCsHL had considerably lower bind ing of the antibody than did DCsNL (Fig. 5f) . We then addressed whether DCsNL and DCsHL differ in the presentation of tumorassociated antigen. We isolated draining lymph nodes from mice with EG7 tumors that express OVA and evaluated the level of pMHC in lymph node DCs. DCsHL had lower expression of pMHC than did DCsNL from the same mice (Fig. 5g) . DCsHL and DCsNL were sorted from lymph nodes of EG7 tumorbearing mice and cultured with OVAspecific OTII T cells. DCsHL induced a lower response of OTII T cells than DCs NL (Fig. 5h) . In contrast, we saw no difference in the T cell response between DCsHL and DCsNL when DCs were loaded with specific peptide before incubation with T cells (Fig. 5i) . Taken together, these data indicate that DCsHL may have defects in processing of tumor associated proteins.
Effects of regulation of lipid levels on DC function in cancer
To identify the potential role of lipid accumulation in abnormal DC function in cancer, we tried to regulate fatty acid levels with an inhibitor of acetylCoA carboxylase, 5(tetradecycloxy)2furoic acid (TOFA) 16 . Because triacylglycerols undergo rapid degradation in the cells, maintaining them in high amounts requires active fatty acid synthesis. We hypothesized that when synthesis is blocked, cells will not be able to sustain high levels of triacylglycerol, even if lipid uptake is increased. When hematopoietic progenitor cells (HPCs) were cultured with TES in the presence of TOFA, it pre vented the accumulation of lipids in DCs (Fig. 6a ) without affecting their viability or causing upregulation of costimulatory molecules or MHC class II (data not shown). Treatment with TOFA consid erably improved the ability of DCs generated in the presence of TES to stimulate allogeneic T cells (Fig. 6b) . To test the effect of TOFA in vivo, we treated EL4 tumor-bearing mice for 2 weeks with TOFAfilled osmotic pumps. At the selected dose (1 μg h −1 ) TOFA did not affect the number of DCs and did not cause changes in the expression of MHC class II or costimulatory molecules (data not shown) but it decreased the presence of lipidladen DCs (Fig. 6c) and restored the ability of DCs to stimulate allogeneic T cells (Fig. 6d) .
To test the possibility that TOFA might improve antitumor response, we immunized EL4 tumor-bearing mice with DCs trans duced with adenovirussurvivin (Adsurv) 17 . Vaccine or TOFA alone had little effect on growth of established tumor (Fig. 6e) . Combining TOFA with the vaccine resulted in a significant (P = 0.041) decrease in tumor growth (Fig. 6e) . In another experimental system, we injected C57BL/6 mice subcutaneously (s.c.) with B16F10 melanoma cells and then vaccinated with the peptide derived from melanoma spe cific protein tyrosinase1. TOFA alone did not affect tumor growth (Fig. 6f) . Vaccine alone caused a temporary decrease in tumor growth, but the combination of TOFA with vaccine yielded significantly (P < 0.01) more potent antitumor effects (Fig. 6f) .
DISCUSSION
This study has demonstrated that a substantial proportion of DCs in tumorbearing hosts have an increased amount of lipids, Figure 3j . T-cell proliferation was measured by 3 [H]-thymidine uptake. Two independent experiments were performed in triplicate. The values of T cell proliferation induced by WT or Msr1-deifient DCs generated without the presence of TES were set as 100%. Values of T cell proliferation induced by DCs generated in the presence of TES are presented as percentage from control level. (f,g) Proliferation of OT-II (f) and OT-I (g) T cells stimulated with DCs with high and normal lipid content sorted from spleens of naive and EL-4 tumor-bearing mice in the presence of 10 μg ml −1 of specific peptides. T cell proliferation was measured in triplicate by 3 [H]-thymidine uptake. In the absence of peptides, 3 [H]-thymidine uptake in all samples was less than 5 × 10 3 c.p.m. Three experiments achieved the same results. (h) Proliferation of OT-II T cells stimulated with CD11c + DCs isolated from spleens of naive and EL-4 tumor-bearing mice and cultured overnight with 1 mg ml −1 OVA or in medium alone. T cell proliferation was measured in triplicate by 3 [H]-thymidine uptake. (i,j) Proliferation of T cells from OT-II (i) and OT-I (j) transgenic mice with DCs with high and normal lipid content sorted from the spleens of EL-4 tumor-bearing mice and incubated overnight with 1 mg ml −1 OVA. T cell proliferation was measured in triplicate using 3 [H]-thymidine uptake. Two experiments obtained similar results. In all panels, means ± s.d. are shown. specifically triglycerides. We obtained these results with several meth ods of lipid detection in multiple tumor models and also in people with cancer across several diagnoses. We reproduced these findings with conditioned medium from tumor explants, indicating that tumorderived factors are responsible for the observed phenom enon. In this study we have tried to determine the mechanism of lipid accumulation in DCs and whether it has any functional con sequences for these cells. Accumulation of lipids might be due to increased synthesis of fatty acids or result from increased lipid uptake from plasma. Our data suggest that the second explanation is more likely (Fig. 3) . Scavenger receptors represent a major route in acquiring fatty acids by DCs and macrophages [18] [19] [20] (Supplementary Discussion) . Our results indicate that DCs from tumorbearing mice have preferential upregulation of Msr1. This is consistent with data demonstrating increased expression of Msr1 on macrophages during culture with ovarian tumor cells 21 . DCs isolated from tumor tissues had substantially higher expression of Msr1 than cells isolated from spleens or lymph nodes, which paral leled the results with lipid level in these cells. An association between the expression of this receptor and lipid levels in DCs was further evident in our analysis of DC subsets. In our study, we observed accu mulation of lipids and upregulation of Msr1 in cDCs but not in pDCs. This was consistent with the results of a study that demonstrated that, in contrast to cDCs, in mouse and human pDCs expression of Msr1 was not detectable 22 . Our experiments with blocking of Msr1 with the soluble scavenger receptor ligand fucoidan 23 and specific antibody, as well as our experiments in Msr1 −/− mice, have demonstrated that upregulation of Msr1 is primarily responsible for increased uptake of exogenous lipids by DCs. It is likely that fatty acids are transferred to DCs in the form of modified lipoproteins. Various lipoprotein modifications have been described in cancer, and those lipoproteins are probably abundant in tumorbearing hosts 24, 25 . It is likely that accumulation of lipids by DCs in vitro and in vivo is due to the pres ence of tumorderived factors that upregulate the expression of Msr1 on DCs, which enables these cells to pick up modified lipoproteins from serum. The nature of such factors remains unclear and requires further investigations (Supplementary Discussion) .
In our studies, lipidladen DCs had a profound defect in their abil ity to process and present soluble antigens. One possible explanation could be that lipidladen DCs are immature cells, which are effective in picking up soluble proteins but have a poor ability to present anti gens. However, the fact that DCsHL and DCsNL expressed similar levels of MHC class II and costimulatory molecules, as well as the fact that peptideloaded DCsHL and DCsNL stimulated specific T cells equally well, argues against this possibility. The molecular mechanisms by which fatty acids affect antigen processing will need further elucidation.
The results of the experiments with inhibition of fatty acid synthesis in tumorbearing mice show that pharmacological downregulation of fatty acids might improve DC function in tumorbearing hosts and antitumor immune responses and suggest that this approach may be useful in enhancing immune responses in people with cancer.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
